Search results
Your search for ���������������������������������:kn39��������� ������ ������ ������ returned no results
Showing 181 to 195 of 728 results for ���������������������������������:know��������� ������ ������ ������
Showing 181 to 195 of 728 results for ���������������������������������:know��������� ������ ������ ������
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)
Evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults.
Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)
Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults.
Cardiovascular disease. Patient decision aid on should I take a statin?
problems, but although some people get them, many people do not. We also do not know how many people would have had those problems even...
We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.
Evidence-based recommendations on VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest. This involves using an artificial lung to oxygenate the blood outside the body.
This guideline covers diagnosing and managing varicose veins in people aged 18 and over. It aims to ensure that people understand the options for treating varicose veins and that healthcare professionals know when to refer people for specialist assessment and treatment.
This guideline covers supporting the social and emotional wellbeing of vulnerable children under 5 through home visiting, childcare and early education. It aims to optimise care for young children who need extra support because they have or are at risk of social or emotional problems.
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.
Medicines management for people receiving social care in the community (QS171)
This quality standard covers assessing if people need help with their medicines and deciding what medicines support is needed to enable people to manage their medicines. It also includes communication between health and social care staff, to ensure people have the medicines support they need. It describes high-quality care in priority areas for improvement.
View quality statements for QS171Show all sections
Guselkumab for treating moderate to severe plaque psoriasis (TA521)
Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults.
This guideline covers keeping adults in care homes safe from abuse and neglect. It includes potential indicators of abuse and neglect by individuals or organisations, and covers the safeguarding process from when a concern is first identified through to section 42 safeguarding enquiries. There are recommendations on policy, training, and care home culture, to improve care home staff awareness of safeguarding and ensure people can report concerns when needed.